GSK's plan to take over the HIV drug market hasn't worked out

GSK's plan to take over the HIV drug market hasn't worked out

Source: 
BioPharma Dive
snippet: 

An FDA rejection and modest sales for two marketed products are challenging GSK's argument that two-drug treatments are a better way to treat HIV.